Menu menu
  • Flux RSS
  • Twitter
  • Facebook
  • Google Plus
  • LinkedIn
  • YouTube

Press releases

Genethon announces expanded collaboration with (...)

2020

Genethon, a French laboratory dedicated to the design and development of gene therapy products for rare diseases, and Sarepta Therapeutics, the leader in precision genetic medicine for rare diseases, today announced an expansion of their collaboration to develop a gene therapy approach for Duchenne muscular dystrophy. Microdystrophin has demonstrated significant efficacy in pre-clinical testing*. The agreement between Sarepta and Genethon paves the way for a clinical trial to begin in 2020. (...)

  • Lire la suite
  • Articles similaires

Conclusive results of a gene therapy trial in (...)

2020

Genethon, which developed the lentiviral vector used and sponsored initial clinical studies, is pleased with the conclusive results of the gene therapy trial underway in the United States and England in X-linked Chronic Septic Granulomatosis (X-CGD), a rare and severe immune dysfunction. Six of the nine patients are free of treatments related to complications generated by the disease. These results have been published in Nature Medicine. Genethon who had conducted initial preclinical and (...)

  • Lire la suite
  • Articles similaires

Algentech Granted US Patent For A Key Genome (...)

2020

ALGENTECH, announces the issuance of a key patent in the field of genome editing by the U.S. Patent Office (U.S. patent number 10457950)The technology claimed by the patent amplifies the effectiveness of gene editing in eukaryotic cells and can be applied in synergy with nucleases, including zinc finger nucleases, TALENs, Crispr-Cas9… Read more

  • Lire la suite
  • Articles similaires

Acticor Biotech announces its participation to the (...)

2019

Acticor Biotech , a clinical stage biotechnology company dedicated to the acute phase of thrombo-embolic diseases, including stroke, announces its participation to the BOOSTER consortium, dedicated to personalized medicine for the management of stroke in emergency situations.

  • Lire la suite
  • Articles similaires

PhinC Development opens subsidiary PhInc. Modeling (...)

2019

Certified, the French company PhinC Development, specialized in simulation and modeling strategy for drug development, strengthens its presence in North America to significantly develop its business and increase its turnover.

  • Lire la suite
  • Articles similaires

Yposkesi, a leading Contract Development and...

2019

Yposkesi, a leading Contract Development and Manufacturing Organization (CDMO) for preferred access and reserved capacity for cGMP grade viral vector production, today announces it produced the viral vectors used in the gene therapy-based clinical trial in patients with Fanconi anemia. In this study, the authors demonstrate for the first time the production of blood cells derived from the patients genetically corrected stem cells. The work on Fanconi anemia patients is published in Nature (...)

  • Lire la suite
  • Articles similaires

Global Bioenergies : A Shareholders’ Meeting will (...)

2019

The agenda of this shareholder’s meeting is to amend the Articles of Association in order to create the position of observer on the Board of Directors, and to appoint BOLD - Business Opportunities for L’Oréal Development to this position in accordance with the announcement made at the last fund-raising event.

  • Lire la suite
  • Articles similaires

Braskem renews partnership with Altar, France-based

2019

In line with its commitment to sustainable development, Braskem, the world’s largest biopolymer producer, announces the renewal of its partnership with Altar, a France-based startup specializing in the development of microorganism lineages in automated cultivation systems. Forged two years ago, the partnership strengthens the company’s strategy for the research and development of renewable (...)

  • Lire la suite
  • Articles similaires

Traaser : Clinical evaluation begins for Diagen™

2019

Clinical evaluation begins for Diagen™ to take patients’ genomic profiles into account along the nephrology care pathway TRAASER, an innovative startup specializing in medical genomics, announces the start of clinical evaluation for its Diagen™ solution as part of the SAGE project, laureate of Bpifrance’s Digital Innovation Competition organized for France’s “Investments for the Future” program, to develop medical genomics for kidney diseases. In collaboration with the Paris AP-HP public (...)

  • Lire la suite
  • Articles similaires

Servier appoints Yposkesi for lentiviral vector (...)

2019

Servier appoints Yposkesi for lentiviral vector GMP-manufacturing in CAR-T cell development technology Service agreement gives Servier access to Yposkesi’s robust production capacity Servier, an international independent pharmaceutical company, and Yposkesi, a leading CDMO for gene therapy viral vector manufacturing, today announce that they have signed a manufacturing service agreement. Servier selected Yposkesi to develop and GMP manufacture lentiviral vectors to support allogenic CAR-T (...)

  • Lire la suite
  • Articles similaires